Related Experiment Video

Updated: Nov 8, 2025

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

531

Pulmonary fibrosis secondary to COVID-19: a narrative review

Suzana Erico Tanni1, Alexandre Todorovic Fabro2, André de Albuquerque3

  • 1Division of Internal Medicine of Botucatu Medical School, São Paulo State University-UNESP, Botucatu, Brazil.

Expert Review of Respiratory Medicine
|April 27, 2021
PubMed

Insights

Pulmonary fibrosis can occur after COVID-19 infection. Early screening and further research are crucial for understanding and managing this serious lung condition.

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pathology

Background:

  • The global increase in COVID-19 cases leads to a rising number of patients developing secondary pulmonary fibrosis.
  • Key aspects of post-COVID-19 pulmonary fibrosis, including risk factors, pathophysiology, and management, remain poorly understood.
  • Pulmonary sequelae post-COVID-19 necessitate its inclusion in the differential diagnosis of pulmonary fibrosis.

Purpose of the Study:

  • To review current evidence on post-COVID-19 pulmonary fibrosis.
  • To emphasize potential risk factors, histopathology, pathophysiology, and clinical features.
  • To discuss potential therapeutic strategies and the need for further research.

Main Methods:

  • A comprehensive literature search was conducted in MEDLINE, Embase, SciELO, and the Cochrane library.
  • The search covered studies published between December 1, 2019, and January 25, 2021.
  • Relevant studies were reviewed and synthesized for this narrative review.

Main Results:

  • Post-COVID-19 pulmonary fibrosis is an emerging clinical concern with incompletely understood characteristics.
  • The review highlights the need to consider COVID-19 as a cause of pulmonary fibrosis.
  • Clinical, tomographic, and functional screening is recommended for patients with prior pulmonary involvement during acute COVID-19.

Conclusions:

  • Pulmonary fibrosis is a potential long-term consequence of COVID-19 infection.
  • Serial screening for pulmonary fibrosis is advised for at-risk individuals post-COVID-19.
  • Further research is essential to elucidate risk factors, biomarkers, pathophysiology, and optimal management strategies.

Keywords:
Coronaviruscovid-19ct-scaninterstitial lung diseaselung functionpost-covid-19pulmonary fibrosispulmonary sequelae

More Related Videos

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia08:05

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia

Published on: December 19, 2020

14.4K
Refined Murine Model of Idiopathic Pulmonary Fibrosis07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

537

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.5K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
1.5K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.6K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.2K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
383
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.8K